Combination of hTERT knockdown and IFN-γ treatment inhibited angiogenesis and tumor progression in glioblastoma

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7186-7195

  George, Joseph ^a   Banik, Naren L ^b   Ray, Swapan K ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL ASSAY; CELL INVASION; COCULTURE; CONTROLLED STUDY; DIFFUSION CHAMBER; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME REGULATION; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; RECOMBINANT PLASMID; REGULATORY MECHANISM; SOLID TUMOR; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; INTERFERON-GAMMA; MICE; MICE, NUDE; MICROCIRCULATION; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; TELOMERASE; TRANSCRIPTION, GENETIC;

EID: 73149097169     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1425     Document Type: Article

References (35)

1. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005;12:585-98.
2. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol 2006;24:1266-72.
3. Combs SE, Widmer V, Thilmann C, HofH, Debus J, Schulz-Ertner D. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 2005;104:2168-73.
4. George J, Gondi CS, Dinh DH, Gujrati M, Rao JS. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res 2007;13:3507-17.
5. George J, Banik NL, Ray SK. Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis, and tumour growth. J Cell Mol Med 2009, doi:10.1111/j.1582-4934.2008.00539.x.
6. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
7. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501.
8. Cairns RA, Khokha R, Hill RP. Molecular mechanisms oftumor invasion and metastasis: an integrated view. Curr Mol Med 2003;3:659-71.
9. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
10. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science 2007;315:1850-3.
11. Carpentier C, Lejeune J, Gros F, et al. Association oftelomerase gene hTERT polymorphism and malignant gliomas. J Neurooncol 2007;84:249-53.
12. Fujiwara T. Telomerase-specific virotherapy for human squamous cell carcinoma. Expert Opin Biol Ther 2009;9:321-9.
13. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Annu Rev Immunol 1997;15:749-95.
14. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89.
15. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
16. Blacken G. Components of the IFN-γ signaling pathway in tumorigenesis. Arch Immunol Ther Exp (Warsz) 2002;50:151-8.
17. George J, Banik NL, Ray SK. Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res 2009;34:66-78. 1
18. George J, Tsutsumi M. siRNA-mediated knockdown ofco nnective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 2007;14:790-803.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
20. Amyot F, Camphausen K, Siavosh A, Sackett D, Gandjbakhche A. Quantitative method to study the network formation of endothelial cells in response to tumor angiogenic factors. IEE Proc Syst Biol 2005;152:61-6.
21. Sckell A, Leunig M. Dorsal skinfold chamber preparation in mice. In: Murray JC, editor. Angiogenesis protocols: methods in molecular medicine. 46. Totowa, New Jersey: Humana Press; 2001, p. 95-105.
22. Wachsberger PR, Burd R, Marero N, et al. Effect ofthe tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 2005;11:835-42.
23. Stern JL, Bryan TM. Telomerase recruitment to telomeres. Cytogenet Genome Res 2008;122:243-54.
24. Osterhage JL, Friedman KL. Chromosome end maintenance by telomerase. J Biol Chem 2009.
25. Wang L, Wei Q, Wang LE, et al. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol 2006;24:1627-32.
26. Belgiovine C, Chiodi I, Mondello C. Telomerase: cellular immortalization and neoplastic transformation. Multiple functions of a multifaceted complex. Cytogenet Genome Res 2008;122:255-62.
27. Falchetti ML, Fiorenzo P, Mongiardi MP, et al. Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurol Res 2006;28:532-37.
28. Lee SH, Kim JW, Oh SH, et al. IFN-γ/IRF-1-induced p27Kip1 down regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer. FEBS Lett 2005;579:1027-33.
29. Plank MJ, Sleeman BD. Tumour-induced angiogenesis: a review. J Theor Med 2003;5:137-53.
30. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
31. Machein MR, Kullmer J, Fiebich BL, Plate KH, Warnke PC. Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 1999;44:732-40.
32. Pallini R, Pierconti F, Falchetti ML, et al. Evidence for telomerase involvement in the angiogenesis ofastr ocytic tumors: expression ofhuman telomerase reverse transcriptase messenger RNA by vascular endothelial cells. J Neurosurg 2001;94:961-71.
33. Falchetti ML, Mongiardi MP, Fiorenzo P, et al. Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int J Cancer 2008;122:1236-42.
34. Shen Y, Zhang YW, Zhang ZX, Miao ZH, Ding J. hTERT-targeted RNA interference inhibits tumorigenicity and motility of HCT 116 cells. Cancer Biol Ther 2008;7:228-36.
35. Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, Smith GM, Forman J. Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis. J Immunol 2000;164:217-22.